New chief clinical officer named at City of Hope Cancer Center Phoenix

Alan H. Bryce, M.D., has joined City of Hope as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope. He joins City of Hope from Mayo Clinic, where he served as chair of the Division of Hematology and Medical Oncology in the Department of Internal Medicine at Mayo Clinic in Arizona and director of Mayo Clinic Comprehensive Cancer Center in Arizona.

“We are excited to welcome Dr. Bryce to City of Hope Cancer Center Phoenix and look forward to his leadership in delivering advanced cancer care to Arizona patients,” said Kevin Tulipana, D.O., M.S., president of City of Hope Cancer Center Phoenix. “He is an accomplished researcher and clinician who, in addition to his leadership role at City of Hope, will swiftly advance the integration of research and clinical efforts that place the patient first.”

Bryce will serve as the region’s senior clinical leader, guiding care across all City of Hope locations in the Phoenix market, including the cancer center in Goodyear and outpatient care centers in Gilbert, North Phoenix and Tatum Ridge.

Commitment to Individualized Medicine

A world-renowned expert in prostate cancer, Bryce has demonstrated how genomics can lead to customized treatment plans unique to each individual. He is known for his commitment to patient-centered cancer care, with a focus on reducing health inequities, enhancing patients’ access to top-quality care and protecting patients’ quality of life. Board certified in internal medicine and medical oncology, Bryce's research centers on developing new therapies and genomic-based approaches to prostate cancer.

Alan Bryce, MD
Alan H. Bryce, M.D.

“This move is motivated by my desire to build a top-quality, coordinated cancer center for the state of Arizona that includes both community and academic practices and enhances access to cancer breakthroughs,” said Bryce. “This is no small task and one where others have tried before, but I am confident that we can succeed. More importantly, this is work that our community needs, and I am excited to meet the challenge.”

At TGen, Bryce will continue his cancer research, including new therapeutic development and immunotherapeutic approaches in prostate cancer, with City of Hope Cancer Center Phoenix providing a significant clinical setting to advance the scientific discoveries made by TGen. His research focuses primarily on clinical trials involving genomics and early therapeutics. Over his career, he has built a robust clinical trials portfolio in genitourinary cancers and melanoma, having launched and led numerous early phase clinical trials to move innovative treatment protocols into the clinic. His interest in genomics includes the use of tumor sequencing for prognostic and predictive information in advanced cancers. He has received clinical trial research funding from the National Cancer Institute continuously since 2013.

“I am delighted to welcome Dr. Bryce to City of Hope and TGen,” said Jeffrey M. Trent, Ph.D., TGen president and research director. “I have had the privilege to work closely with him for over a decade, in efforts to use genomics to better individualize patients' cancer treatment. His leadership role in national clinical trials for prostate cancer, and the broad range of cancer types for which he has clinical experience, including melanoma and early phase clinical trials, make him an outstanding addition to City of Hope’s advanced cancer care in Arizona and nationally.”